This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
RANCHO CORDOVA, Calif., Sept. 19, 2012 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, today said it has signed two additional new channel partner agreements as part of its continuing program to enhance its distribution, technical service and clinical support initiatives of its cord blood products.
Under a new agreement with HVD Biotech Vertriebs GmbH ("HVD"), HVD will have exclusive distribution rights for the AXP
® System and BioArchive
® System in 10 European countries—including Germany, Austria, and the Czech Republic—and 13 Middle Eastern countries, including Egypt, Saudi Arabia and the United Arab Emirates.
The Company also announced an expanded distribution agreement with Comércio Exportação e Importação de Materiais Médicos Ltda ("CEI"), under which CEI will have exclusive distribution rights for the AXP and BioArchive in nine Latin American countries, including Mexico, Brazil, and Argentina. CEI has been distributing the BioArchive System and ThermoGenesis manual cord blood processing and storage sets for cryopreservation of 25mL concentrated samples in Latin American countries since 2000.
"These new integrated agreements, combined with our recently announced distribution agreement in other European markets with Concessus are important milestones in our strategy to provide a customer-centric focus that incorporates sales, service and support for our cord blood product portfolio. We believe these new partners will further both our existing customer relationships and market expansion efforts for our best-in-class offerings," said Hal Baker, Vice President of Commercial Operations for ThermoGenesis.
"We look forward to working with ThermoGenesis on further developing these important European and Middle Eastern markets. We believe there are significant opportunities with cord blood banks in these regions and that ThermoGenesis' offerings provide important competitive advantages," said Hermanus van Duyne, Managing Director of HVD.
"We have had a very positive experience with ThermoGenesis over the past 12 years and are excited about the new market opportunities under our expanded relationship with the Company," said Paulo Pacheco, Chief Executive Officer of CEI.